ENSG00000100345 |
|
melanoma |
frameshift_variant |
16.83% (17/101) |
2 entries |
ENSG00000100345 |
|
basal cell carcinoma |
stop_gained |
18.97% (11/58) |
1 entry |
ENSG00000100345 |
|
colorectal adenocarcinoma |
frameshift_variant |
7.185% (86/1197) |
2 entries |
ENSG00000100345 |
|
breast ductal adenocarcinoma |
sequence_alteration |
9.724% (60/617) |
1 entry |
ENSG00000100345 |
|
colorectal adenocarcinoma |
conservative_inframe_deletion |
7.185% (86/1197) |
2 entries |
ENSG00000100345 |
|
melanoma |
conservative_inframe_deletion |
16.83% (17/101) |
1 entry |
ENSG00000100345 |
|
breast ductal adenocarcinoma |
missense_variant |
9.724% (60/617) |
1 entry |
ENSG00000100345 |
|
breast ductal adenocarcinoma |
conservative_inframe_deletion |
9.724% (60/617) |
1 entry |
ENSG00000100345 |
|
basal cell carcinoma |
missense_variant |
18.97% (11/58) |
1 entry |
ENSG00000100345 |
|
melanoma |
missense_variant |
16.83% (17/101) |
1 entry |
ENSG00000100345 |
|
colorectal adenocarcinoma |
sequence_alteration |
7.185% (86/1197) |
1 entry |
ENSG00000100345 |
|
colorectal adenocarcinoma |
missense_variant |
7.185% (86/1197) |
2 entries |
ENSG00000100345 |
|
hemangioblastoma |
sequence_alteration |
34.38% (11/32) |
1 entry |
ENSG00000100345 |
|
colorectal adenocarcinoma |
stop_gained |
7.185% (86/1197) |
1 entry |
ENSG00000100345 |
|
gastric adenocarcinoma |
stop_gained |
4.713% (32/679) |
1 entry |
ENSG00000100345 |
|
rectal adenocarcinoma |
missense_variant |
1.31% (3/229) |
1 entry |
ENSG00000100345 |
|
brain glioblastoma |
missense_variant |
0.54% (5/926) |
1 entry |
ENSG00000100345 |
|
nasopharyngeal squamous cell carcinoma |
conservative_inframe_deletion |
2.395% (4/167) |
1 entry |
ENSG00000100345 |
|
squamous cell lung carcinoma |
sequence_alteration |
2.493% (19/762) |
1 entry |
ENSG00000100345 |
|
osteosarcoma |
sequence_alteration |
3.448% (4/116) |
1 entry |
ENSG00000100345 |
|
prostate carcinoma |
sequence_alteration |
2.113% (9/426) |
2 entries |
ENSG00000100345 |
|
ovarian serous adenocarcinoma |
missense_variant |
1.04% (7/673) |
2 entries |
ENSG00000100345 |
|
oral squamous cell carcinoma |
missense_variant |
1.456% (3/206) |
3 entries |
ENSG00000100345 |
|
diffuse large B-cell lymphoma |
missense_variant |
0.9901% (3/303) |
2 entries |
ENSG00000100345 |
|
esophageal squamous cell carcinoma |
stop_gained |
2.37% (16/675) |
3 entries |
ENSG00000100345 |
|
hepatocellular carcinoma |
sequence_alteration |
1.774% (16/902) |
1 entry |
ENSG00000100345 |
|
colon adenocarcinoma |
stop_gained |
4.026% (31/770) |
1 entry |
ENSG00000100345 |
|
chronic lymphocytic leukemia |
missense_variant |
1.239% (11/888) |
1 entry |
ENSG00000100345 |
|
squamous cell lung carcinoma |
missense_variant |
2.493% (19/762) |
2 entries |
ENSG00000100345 |
|
hemangioblastoma |
missense_variant |
34.38% (11/32) |
1 entry |
ENSG00000100345 |
|
prostate adenocarcinoma |
conservative_inframe_deletion |
3.164% (46/1454) |
1 entry |
ENSG00000100345 |
|
HER2 Positive Breast Carcinoma |
missense_variant |
9.848% (13/132) |
2 entries |
ENSG00000100345 |
|
bladder carcinoma |
missense_variant |
4.324% (24/555) |
1 entry |
ENSG00000100345 |
|
colon adenocarcinoma |
missense_variant |
4.026% (31/770) |
6 entries |
ENSG00000100345 |
|
Cervical Small Cell Carcinoma |
missense_variant |
33.33% (2/6) |
1 entry |
ENSG00000100345 |
|
female breast carcinoma |
missense_variant |
1.124% (3/267) |
2 entries |
ENSG00000100345 |
|
prostate carcinoma |
missense_variant |
2.113% (9/426) |
2 entries |
ENSG00000100345 |
|
colon adenocarcinoma |
frameshift_variant |
4.026% (31/770) |
1 entry |
ENSG00000100345 |
|
cecum adenocarcinoma |
missense_variant |
6.818% (9/132) |
1 entry |
ENSG00000100345 |
|
prostate adenocarcinoma |
missense_variant |
3.164% (46/1454) |
2 entries |
ENSG00000100345 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.6702% (5/746) |
2 entries |
ENSG00000100345 |
|
breast carcinoma |
sequence_alteration |
1.772% (25/1411) |
1 entry |
ENSG00000100345 |
|
chronic lymphocytic leukemia |
sequence_alteration |
1.239% (11/888) |
1 entry |
ENSG00000100345 |
|
embryonal rhabdomyosarcoma |
missense_variant |
2.632% (2/76) |
1 entry |
ENSG00000100345 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
9.412% (8/85) |
2 entries |
ENSG00000100345 |
|
papillary renal cell carcinoma |
missense_variant |
0.8451% (3/355) |
1 entry |
ENSG00000100345 |
|
skin melanoma |
sequence_alteration |
1.965% (19/967) |
3 entries |
ENSG00000100345 |
|
small cell lung carcinoma |
frameshift_variant |
0.9375% (3/320) |
2 entries |
ENSG00000100345 |
|
diffuse gastric adenocarcinoma |
missense_variant |
6.329% (5/79) |
3 entries |
ENSG00000100345 |
|
breast carcinoma |
missense_variant |
1.772% (25/1411) |
1 entry |
ENSG00000100345 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
2.395% (4/167) |
1 entry |
ENSG00000100345 |
|
angiosarcoma |
sequence_alteration |
15.38% (2/13) |
1 entry |
ENSG00000100345 |
|
female breast carcinoma |
sequence_alteration |
1.124% (3/267) |
1 entry |
ENSG00000100345 |
|
skin melanoma |
stop_gained |
1.965% (19/967) |
1 entry |
ENSG00000100345 |
|
colon adenocarcinoma |
sequence_alteration |
4.026% (31/770) |
2 entries |
ENSG00000100345 |
|
skin melanoma |
missense_variant |
1.965% (19/967) |
2 entries |
ENSG00000100345 |
|
esophageal adenocarcinoma |
missense_variant |
4.566% (20/438) |
1 entry |
ENSG00000100345 |
|
breast carcinoma |
conservative_inframe_deletion |
1.772% (25/1411) |
1 entry |
ENSG00000100345 |
|
gastric adenocarcinoma |
missense_variant |
4.713% (32/679) |
1 entry |
ENSG00000100345 |
|
pharyngeal squamous cell carcinoma |
missense_variant |
6.452% (2/31) |
2 entries |
ENSG00000100345 |
|
gastric adenocarcinoma |
sequence_alteration |
4.713% (32/679) |
1 entry |
ENSG00000100345 |
|
hepatocellular carcinoma |
missense_variant |
1.774% (16/902) |
1 entry |
ENSG00000100345 |
|
clear cell renal carcinoma |
missense_variant |
0.4354% (6/1378) |
3 entries |
ENSG00000100345 |
|
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
1.126% (5/444) |
2 entries |
ENSG00000100345 |
|
myelodysplastic syndrome |
sequence_alteration |
2.703% (2/74) |
1 entry |
ENSG00000100345 |
|
prostate adenocarcinoma |
sequence_alteration |
3.164% (46/1454) |
1 entry |
ENSG00000100345 |
|
lung adenocarcinoma |
stop_gained |
2.489% (29/1165) |
1 entry |
ENSG00000100345 |
|
esophageal squamous cell carcinoma |
missense_variant |
2.37% (16/675) |
3 entries |
ENSG00000100345 |
|
lung adenocarcinoma |
missense_variant |
2.489% (29/1165) |
6 entries |
ENSG00000100345 |
|
esophageal squamous cell carcinoma |
conservative_inframe_deletion |
2.37% (16/675) |
1 entry |
ENSG00000100345 |
|
Mantle cell lymphoma |
sequence_alteration |
2.439% (1/41) |
1 entry |
ENSG00000100345 |
|
colon adenocarcinoma |
conservative_inframe_deletion |
4.026% (31/770) |
1 entry |
ENSG00000100345 |
|
ovarian serous adenocarcinoma |
stop_gained |
1.04% (7/673) |
1 entry |
ENSG00000100345 |
|
Pleural Mesothelioma |
stop_gained |
0.7843% (2/255) |
1 entry |
ENSG00000100345 |
|
bladder transitional cell carcinoma |
missense_variant |
0.7299% (1/137) |
1 entry |
ENSG00000100345 |
|
Pleural Epithelioid Mesothelioma |
stop_gained |
0.6329% (1/158) |
1 entry |
ENSG00000100345 |
|
Pleural Biphasic Mesothelioma |
stop_gained |
2.899% (2/69) |
1 entry |
ENSG00000100345 |
|
non-small cell lung carcinoma |
sequence_alteration |
3.774% (2/53) |
1 entry |
ENSG00000100345 |
|
head and neck squamous cell carcinoma |
amino_acid_insertion |
0.6702% (5/746) |
1 entry |
ENSG00000100345 |
|
brain glioblastoma |
sequence_alteration |
0.54% (5/926) |
1 entry |
ENSG00000100345 |
|
large cell lung carcinoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000100345 |
|
clear cell renal carcinoma |
sequence_alteration |
0.4354% (6/1378) |
1 entry |
ENSG00000100345 |
|
esophageal squamous cell carcinoma |
frameshift_variant |
2.37% (16/675) |
1 entry |
ENSG00000100345 |
|
Invasive Breast Carcinoma |
frameshift_variant |
8.511% (4/47) |
1 entry |
ENSG00000100345 |
|
Invasive Breast Carcinoma |
stop_gained |
8.511% (4/47) |
1 entry |
ENSG00000100345 |
|
rectal adenocarcinoma |
conservative_inframe_deletion |
1.31% (3/229) |
1 entry |
ENSG00000100345 |
|
pancreatic ductal adenocarcinoma |
stop_gained |
3.892% (49/1259) |
1 entry |
ENSG00000100345 |
|
hepatocellular carcinoma |
frameshift_variant |
1.774% (16/902) |
1 entry |
ENSG00000100345 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
0.6329% (1/158) |
1 entry |
ENSG00000100345 |
|
Invasive Breast Carcinoma |
conservative_inframe_deletion |
8.511% (4/47) |
1 entry |
ENSG00000100345 |
|
small cell lung carcinoma |
amino_acid_insertion |
0.9375% (3/320) |
1 entry |
ENSG00000100345 |
|
clear cell renal carcinoma |
stop_gained |
0.4354% (6/1378) |
1 entry |
ENSG00000100345 |
|
bronchoalveolar adenocarcinoma |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000100345 |
|
large cell lung carcinoma |
stop_gained |
5.556% (1/18) |
1 entry |
ENSG00000100345 |
|
cecum adenocarcinoma |
conservative_inframe_deletion |
6.818% (9/132) |
1 entry |
ENSG00000100345 |
|
brain glioblastoma |
conservative_inframe_deletion |
0.54% (5/926) |
1 entry |
ENSG00000100345 |
|
Pleural Biphasic Mesothelioma |
missense_variant |
2.899% (2/69) |
1 entry |
ENSG00000100345 |
|
Cortisol-Producing Adrenal Cortex Adenoma |
conservative_inframe_deletion |
0.8065% (1/124) |
1 entry |
ENSG00000100345 |
|
Cervical Small Cell Carcinoma |
stop_gained |
33.33% (2/6) |
1 entry |
ENSG00000100345 |
|
chromophobe renal cell carcinoma |
missense_variant |
0.8696% (1/115) |
1 entry |
ENSG00000100345 |
|
gastric adenocarcinoma |
conservative_inframe_deletion |
4.713% (32/679) |
1 entry |
ENSG00000100345 |
|
alveolar rhabdomyosarcoma |
missense_variant |
1.695% (1/59) |
1 entry |
ENSG00000100345 |
|
head and neck squamous cell carcinoma |
stop_gained |
0.6702% (5/746) |
1 entry |
ENSG00000100345 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
9.412% (8/85) |
1 entry |
ENSG00000100345 |
|
lung adenocarcinoma |
conservative_inframe_deletion |
2.489% (29/1165) |
1 entry |
ENSG00000100345 |
|
Invasive Breast Carcinoma |
missense_variant |
8.511% (4/47) |
1 entry |
ENSG00000100345 |
|
adrenal cortex carcinoma |
missense_variant |
0.6098% (1/164) |
1 entry |
ENSG00000100345 |
|
ependymoma |
sequence_alteration |
2.174% (1/46) |
1 entry |
ENSG00000100345 |
|
pharyngeal squamous cell carcinoma |
stop_gained |
6.452% (2/31) |
1 entry |
ENSG00000100345 |
|
lung adenocarcinoma |
sequence_alteration |
2.489% (29/1165) |
1 entry |
ENSG00000100345 |
|
skin melanoma |
frameshift_variant |
1.965% (19/967) |
1 entry |
ENSG00000100345 |
|
renal cell carcinoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000100345 |
|
Pleural Mesothelioma |
frameshift_variant |
0.7843% (2/255) |
1 entry |
ENSG00000100345 |
|
small cell lung carcinoma |
missense_variant |
0.9375% (3/320) |
1 entry |
ENSG00000100345 |
|
Merkel cell skin cancer |
sequence_alteration |
3.333% (1/30) |
1 entry |
ENSG00000100345 |
|
Pleural Mesothelioma |
missense_variant |
0.7843% (2/255) |
1 entry |
ENSG00000100345 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
21.05% (4/19) |
1 entry |
ENSG00000100345 |
|
anaplastic astrocytoma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000100345 |
|
pulmonary blastoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000100345 |
|
Malignant Germ Cell Tumor |
missense_variant |
100.0% (1/1) |
1 entry |
ENSG00000100345 |
|
dedifferentiated chondrosarcoma |
missense_variant |
7.143% (1/14) |
1 entry |
ENSG00000100345 |
|
Pancreatic Acinar Cell Carcinoma |
sequence_alteration |
5.0% (1/20) |
1 entry |